News | September 07, 2008

Cardiolite Highlights Role in Molecular Breast Imaging Trial

September 7, 2008 - Cardiolite (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection) by Lantheus Medical Imaging will be featured in a new study on molecular breast imaging being presented on Sunday, Sept. 7 2008, the company announced at the American Society of Clinical Oncology’s 2008 Breast Cancer Symposium in Washington, D.C.

Cardiolite, formerly marketed as Miraluma for the breast cancer imaging indication, is FDA approved for planar imaging as a second line diagnostic drug after mammography to assist in the evaluation of breast lesions in patients with an abnormal mammogram or a palpable breast mass. Cardiolite is not indicated for breast cancer screening, or to confirm the presence or absence of a malignancy, or in place of a mammogram, and it is not an alternative to biopsy. This imaging test is used to assist in the evaluation of breast lesions in some women who have had an abnormal mammogram, or who have a palpable breast mass. In this test, a woman receives an injection of a small amount of a short-lived radioactive substance called Cardiolite, which is taken up by cancer cells, and a gamma camera is used to obtain images of the breasts.

“This promising new study on molecular breast imaging provides encouraging data for millions of women and families who are impacted by breast cancer and sheds light on potential new diagnostic approaches for finding tumors in women who have dense breast tissue, which can confound mammograms,” stated Don Kiepert, president and chief executive officer of Lantheus Medical Imaging. “We are proud to supply the imaging agent for this important clinical effort. Breast cancer is a devastating disease and we recognize how important and valuable early detection is for women.”

For more information: www.lantheus.com

Related Content

ISMRM Issues Guidelines for MRI Gadolinium Contrast Agents
News | Contrast Media | August 15, 2017
The International Society for Magnetic Resonance in Medicine (ISMRM) has provided new guidance in the use of contrast...
Contrast Media from Bayer, trends in contrast media and developments in contrast media
Feature | Contrast Media | July 28, 2017 | By Dave Fornell
Here are several updates in medical imaging ...
Guerbet Announces Plans to Streamline Contrast Media Portfolio, gadolinium MRI contrast
News | Contrast Media | July 18, 2017
July 18, 2017 — Guerbet recently announced that it will phase out sales throughout the world of two products: Hexabri
ACR Offers Revised Contrast Media in Imaging Manual
News | Contrast Media | July 17, 2017
The American College of Radiology (ACR) recently revised its authoritative guide for the safe and effective use of...
FDA says gadolinium retention in the brain is not a safety issue
Feature | Magnetic Resonance Imaging (MRI) | May 25, 2017
A U.S. Food and Drug Administration (FDA) review of the safety ramifications of gadolinium-based contrast agents for...
Targeted MRI Could Pinpoint Aggressive Prostate Cancers Before They Spread

The ZD2-Gd probe, represented by the orange ball and green arrow, binds to the EDB-FN in the prostate cancer cells with high metastatic potential. This results in a strong MRI signal (upper right). Prostate cancer cells with low metastatic potential have no EDB-FN and so there is no MRI signal (lower right). Credit: Han, et al., Bioconjug Chem-Apr-2017

News | Prostate Cancer | May 24, 2017
A research team funded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) has engineered a...
Scientists Develop Novel Chemical Dye to Improve MRI Liver Cancer Imaging
News | Magnetic Resonance Imaging (MRI) | May 03, 2017
May 3, 2017 — Scientists from the National University of Singapore (NUS) have developed a novel nanodiamond-based ...
Sponsored Content | Case Study | Contrast Media Injectors | April 13, 2017
The volume of computed tomography (CT) imaging exams continues to grow in the United States,[2] adding pressure to...
PRAC, European Medicines Agency, gadolinium-based contrast agents, safety recommendations, brain MRI
News | Contrast Media | March 13, 2017
The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency recently released new...
Overlay Init